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Generation of genetically engineered mouse models
(GEMMs) for chromosomal translocations in the
endogenous loci by a knockin strategy is lengthy
and costly. The CRISPR/Cas9 system provides an
innovative and flexible approach for genome engi-
neering of genomic loci in vitro and in vivo. Here,
we report the use of the CRISPR/Cas9 system for
engineering a specific chromosomal translocation
in adult mice in vivo. We designed CRISPR/Cas9 len-
tiviral vectors to induce cleavage of the murine
endogenous Eml4 and Alk loci in order to generate
the Eml4-Alk gene rearrangement recurrently found
in non-small-cell lung cancers (NSCLCs). Intratra-
cheal or intrapulmonary inoculation of lentiviruses
induced Eml4-Alk gene rearrangement in lung cells
in vivo. Genomic and mRNA sequencing confirmed
the genome editing and the production of the Eml4-
Alk fusion transcript. All mice developed Eml4-Alk-
rearranged lung tumors 2 months after the inocula-
tion, demonstrating that the CRISPR/Cas9 system
is a feasible and simple method for the generation
of chromosomal rearrangements in vivo.
INTRODUCTION
Chromosomal rearrangements are key causative events in
several types of human cancers (Gostissa et al., 2011; Mitelman
et al., 2007). The generation of genetically engineered mouse
models (GEMMs) that faithfully recapitulate chromosomal rear-
rangements have been instrumental to advance the understand-
ing of the biology and therapy of cancer (Rabbitts et al., 2001).
However, design and generation of GEMMs for chromosomal re-
arrangements targeted in the endogenous loci is expensive and
time consuming. The bacterial type II clustered regularly inter-
spaced short palindromic repeat (CRISPR)/CRISPR-associated
(Cas) systems have recently shown great potential for RNA-Cell Reguidedgenomeediting, includingmultiplexing genomeengineer-
ing (Cong et al., 2013; Mali et al., 2013), homologous recombina-
tion and gene targeting (Wang et al., 2013; Yang et al., 2013), and
regulation of transcription (Gilbert et al., 2013). CRISPR/Cas9
systems have been successfully used for precise genome editing
in mouse embryonic stem cells (ESCs) and targeted biallelic
mutagenesis in F0 zebrafish (Jao et al., 2013; Wang et al., 2013;
Yang et al., 2013). Recently, CRISPR-Cas9 systems have been
used to efficiently edit the genome of adult mice in vivo in liver
and muscle (Long et al., 2014; Xue et al., 2014; Yin et al., 2014).
The RNA-guided Cas9 endonuclease induces sequence-spe-
cific DNA double-strand breaks (DSBs) that are repaired mostly
by the classical and alternative nonhomologous end-joining
pathways (c-NHEJ or AEJ) or by homology-directed repair
(HDR) (Boboila et al., 2012). The DSB repair mediated by end-
joining pathways can lead to insertion/deletion (indel) mutations,
but it can also be inappropriately resolved into a chromosomal
rearrangement (Alt et al., 2013; Chiarle et al., 2011; Klein et al.,
2011). During the last few years, several studies demonstrated
that DSBs generated by genome editing tools like zinc-finger
nucleases (ZFNs) and transcription activator-like effector nucle-
ases (TALENs) can be resolved into chromosomal rearrange-
ments in human cell lines (Brunet et al., 2009; Lee et al., 2012;
Piganeau et al., 2013) and zebrafish (Gupta et al., 2013; Xiao
et al., 2013). Similarly, recent reports in cell lines in vitro demon-
strated the potential application of the CRISPR/Cas9 system to
induce, at high frequency, targeted cancer-associated chromo-
somal rearrangements in human cell lines, such as EML4-ALK,
CD74-ROS1, KIF5B-RET, EWSR1-FLI1, and AML1-ETO rear-
rangements, by designing pairs of specific guide RNAs for the
loci of interest (Choi and Meyerson, 2014; Torres et al., 2014).
EML4-ALK rearrangement is found in about 5%–7% of non-
small-cell lung cancers (NSCLCs) and is one of themost frequent
rearrangements in solid human cancers (Chiarle et al., 2008;
Soda et al., 2007). In NSCLC, the EML4-ALK rearrangement is
generated by an inversion of a chromosomal segment of 12
Mb on human chromosome 2 with breakpoints in intron 19 of
the human ALK gene and variable breakpoints in the EML4
gene, the most frequent being in intron 13 (Mano, 2008). This
chromosomal inversion generates an EML4-ALK fusion proteinports 9, 1219–1227, November 20, 2014 ª2014 The Authors 1219
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Figure 1. Generation of Eml4-Alk Rearrangements by the CRISPR/Cas9 System in Mouse Cells In Vitro
(A) Schematic representation of the CRISPR/Cas9-generated DSBs in the intron 19 of the Alk locus and in intron 13 of the Eml4 locus. Simultaneous generation of
DSBs induces a chromosomal inversion of 10 Mb, leading to the generation of the Eml4-Alk chromosomal rearrangement.
(B) Schematic representation of base pairing between Alk and Eml4 genomic loci and targeting sgRNAs. Red arrow indicates putative cleavage site.
(C) SURVEYOR assay for CRISPR/Cas9-mediated indels in the Alk and Eml4 genomic loci.
(D) Detection of Eml4-Alk rearrangements by PCR on genomic DNA extracted from ASB-XIV lung cell line transduced with lentivirus expressing the Cas9
nuclease (vector) alone or together with Eml4 or Alk sgRNA. Black arrows indicate PCR primers designed in intron 19 of the Alk locus and intron 13 of the
Eml4 locus.
(legend continued on next page)
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that has constitutive tyrosine kinase activity that drives NSCLC
growth (Chiarle et al., 2008; Shaw and Engelman, 2013).
In this study, we show the CRISPR/Cas9 system can be ex-
ploited to directly engineer Eml4-Alk rearrangements in vivo in
adult mice. As a consequence of Eml4-Alk rearrangement induc-
tion, mice developed lung tumors within a short period of time.
Therefore, this approach represents a simple and cost-effective
method to model chromosomal rearrangements that could be
used as an alternative to classical transgenic or knockin mice
for a variety of biological and cancer studies.
RESULTS
Generation of Eml4-Alk Rearrangements and Eml4-Alk
Fusion mRNA In Vitro by the CRISPR/Cas9 System
We engineered lentiviral vectors expressing Cas9 endonuclease
and single-guide RNA (sgRNA) specific for either the Eml4 or the
Alk mouse genomic locus. As the mouse Eml4 gene has a non-
coding exon 1, which is lacking in human EML4, we designed
sgRNAs to target intron 14 of the mouse Eml4 gene, which is
the equivalent of intron 13 of the human EML4 gene. However,
for parallelism with the human EML4-ALK rearrangement in
NSCLC, in this paper, we will refer to this as intron 13. In the
mouse Alk gene, the sgRNAs were designed to target intron 19
as in human EML4-ALK rearrangements, in order to generate
DSBs in that position and eventually obtain a chromosomal
breakpoint comparable to those found in humanNSCLC (Figures
1A and 1B). Out of several independent sgRNAs, we selected the
most efficient sequences by SURVEYOR assay for further use
(Cong et al., 2013) (Figure 1C).
Next, we tested whether the combination of the two lentivi-
ruses encoding Eml4 and Alk sgRNAs would induce Eml4-Alk
rearrangements at detectable frequency in murine cells. We
transduced either murine immortalized tail fibroblasts or a mu-
rine lung carcinoma cell line (ASB-XIV) with single or both len-
tiviruses. Six days after transduction, the genomic product
corresponding to the Eml4-Alk rearrangement was readily
detectable in both cell types only when both Eml4 andAlk sgRNA
lentiviruses were used (Figures 1D and S1A). We Sanger
sequenced several independent genomic breakpoint junctions
to show that the CRISPR/Cas9 system can generate either pre-
cise genomic junctions originated by direct repair of the pre-
dicted DNA cleavage sites (three bases on the 50 end of the
PAM sequence) or junctions with base insertions or deletions,
a process consistent with editing by NHEJ (Alt et al., 2013) (Fig-
ure 1E). As predicted by the genomic breakpoint, such engi-
neered Eml4-Alk rearrangements should produce in-frame
fusion Eml4-Alk mRNA transcripts joining coding exons 1–13 of
the Eml4 gene and exons 20–29 of the Alk gene. Indeed, we de-
tected in both cell lines mRNA fusion transcripts encoding for an
in-frame EML4-ALK chimeric protein identical to that found in
human NSCLC (Figures 1F, 1G, and S1B). Thus, the CRISPR/(E) Examples of chromatograms showing a single base insertion, a microdeletion
deleted bases; green bases, insertions or mutations. Pred., sequence of the pre
(F) Detection of Eml4-Alk fusion transcripts in ASB-XIV cell line transduced with le
exon13 of Eml4 and exon 20 of Alk genes. Black arrows indicate the position of
(G) An example chromatogram showing the fusion transcripts producing an in-fr
Cell ReCas9 system can efficiently generate the desired chromosomal
rearrangement by introducing DSBs in the targeted sites.
Other chromosomal events could be predicted as the result of
the simultaneous activity of CRISPR/Cas9 on the Eml4 and Alk
loci located on the two alleles of chromosome 17. It is well known
that DSBs generated by nucleases located in cis on the same
chromosomal allele can result in deletions of the chromosome
portion between the two DSBs in the immunoglobulin H (IgH) lo-
cus (Zarrin et al., 2007) as well as in other genomic loci (Gostissa
et al., 2014). This general propensity of intrachromosomal DSBs
to be frequently joined, even at long distances, could be the
result of the nuclear architecture of chromosomal territories
(Hakim et al., 2012; Zhang et al., 2012). Thus, we investigated
whether intrachromosomal deletions were generated by the
simultaneous activity of CRISPR/Cas9 on the Eml4 and Alk
genes (Figure S1C). Indeed, in both fibroblast and lung cells,
we found genomic junctions that corresponded to a deletion of
the 10 Mb region between the Eml4 and Alk on chromosome
17 (Figure S2A). In addition to deletions, other complex chromo-
somal rearrangements could be also predicted, including the for-
mation of dicentric or acentric chromosomes, when DSBs on
both alleles of the Eml4 or the Alk locus are joined (Figure S1C).
However, we did not detect such rearrangements by PCR, indi-
cating that they could be rare or alternatively be lost during cell
replication because genetically unstable. Finally, we found
genomic junctions between the intron 13 of Eml4 and intron 19
of Alk (Figure S2B). These could be explained either as large
10 Mb deletion circles (Figure S1C) or as interchromosomal
translocations with duplication of the 10 Mb region between
the Eml4 and the Alk loci (Figure S1C). Therefore, we concluded
that engineering the genome with CRISPR/Cas9 system in two
independent loci leads to several genomic rearrangements that
can be predicted by the position of the targeted loci.
Generation of Eml4-Alk Rearrangements and Eml4-Alk
Fusion mRNA In Vivo by the CRISPR/Cas9 System
Next, we tested whether Eml4-Alk rearrangements could be ob-
tained in vivo in adult mice. Since Eml4-Alk rearrangements are
mostly found in human NSCLC, we delivered lentiviral particles
to lungs of adult mice either by intratracheal inoculation (Simp-
son et al., 2001) or by direct intrapulmonary injection (Onn
et al., 2003) (Figure 2A). We inoculated mice with both lentivi-
ruses expressing Cas9/Alk sgRNA and Cas9/Eml4 sgRNA. As
controls, we inoculated mice with lentiviruses expressing Cas9
without sgRNA or expressing Eml4 sgRNA or Alk sgRNA alone.
After 6 days of lentiviral inoculation, we took the lungs for DNA
isolation in order to investigate the presence of Eml4-Alk rear-
rangements by PCR and sequencing. Following intratracheal
inoculation or intrapulmonary injections, we detected Eml4-Alk
rearrangements inmice injectedwith both Eml4 andAlk sgRNAs,
but not in controls (Figure 2B). The pattern of genomic junctions
was similar to those obtained in cells in vitro, with perfectin the Alk intron, and a microdeletion in the Eml4 intron. Red or blue dashes,
dicted genomic junction of Eml4-Alk rearrangement.
ntiviral vectors as indicated in (D). RT-PCR shows a fusion transcript between
PCR primers.
ame EML4-ALK chimeric protein.
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Figure 2. In Vivo Generation of Eml4-Alk Rearrangements in Mice
(A) Schematic diagrams showing intratracheal inoculations (I.T.) or intrapulmonary injections (I.P.) of CRISPR/Cas9 lentivirus and isolation of lung epithelial
cells.
(legend continued on next page)
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junctions or indels (Figure 2C). Remarkably, we also found in vivo
genomic junctions corresponding to a 10 Mb deletion or to an
interchromosomal translocation between the Eml4 and Alk
genomic loci (Figures S3A and S3B). To determine frequency
of cells in vivo carrying the genomic Eml4-Alk rearrangement,
or other genomic events such as 10 Mb deletions, after Eml4
and Alk sgRNA lentiviral infection, we applied a technique previ-
ously used to determine the frequency in cell populations of
chromosomal translocations such as IgH/c-myc in B lympho-
cytes (Chiarle et al., 2011). By this approach, in four independent
mice, we found 17 Eml4-Alk rearrangements in 114 independent
PCR reactions each from 105 cells. All the PCR products were
sequenced and confirmed to have the expected genomic
Eml4-Alk rearrangement. No Eml4-Alk rearrangements were
found in 152 independent PCR reactions from control mice
(i.e., in cells from mice infected with either empty or Alk
sgRNA-only lentivirus). Thus, we calculated that the frequency
of Eml4-Alk inversion in vivo was approximately 1.5 rearrange-
ments/106 cells for the amount of lentivirus and the technique
we used. When we studied the genomic product resulting from
the 10 Mb deletion, we found and confirmed by sequencing
PCR products corresponding to genomic deletion in 10 out of
38 independent PCR reactions from mice infected with both
Eml4 and Alk sgRNAs and in 0 out of 38 controls, giving an esti-
mated frequency of 2.6 deletions/106 cells. Finally, by isolating
mRNA, we found fusion transcripts coding for an in-frame
EML4-ALK chimeric protein as predicted by the genomic break-
point (Figure 2D). Thus, direct delivery of CRISPR/Cas9 elements
to epithelial lung cells can efficiently generate DNA DSBs in vivo
that are resolved into chromosomal rearrangements.
Eml4-Alk Inversion Inducedby theCRISPR/Cas9System
Drives Tumor Development in Lungs
A critical point was to determine whether the generation of Eml4-
Alk rearrangements by the CRISPR/Cas9 system was sufficient
to drive transformation of lung epithelial cells and therefore lung
tumor formation. Transgenic expression of the human EML4-
ALK cDNA under either a surfactant protein C (SPC) promoter
(Soda et al., 2008) or under a biscistronic CC10-rtTA doxycy-
cline-inducible promoter (Chen et al., 2010) induces the forma-
tion of lung tumors. We also developed a GEMMwith transgenic
expression of human EML4-ALK under the SPC promoter and
observed tumor formation with 100% penetrance. Tumor forma-
tion was further accelerated by heterozygous or homozygous
deletion of p53 (C.V. and R.C., unpublished data). Therefore, to
investigate whether the generation of Eml4-Alk rearrangements
was sufficient to induce lung tumor formation, we injected
CRISPR/Cas9 lentivirus expressing Eml4 and Alk sgRNAs in
p53+/ or p53/mice. Mice were sacrificed 8weeks after the in-
jection, and lungs were analyzed for the presence of tumors by
histology and immunohistochemistry. We found lung tumors in
six out of six p53/ mice and in four out of four p53+/ mice,(B) PCR assay 6 days after lentivirus injections demonstrates that Eml4-Alk rearran
Alk sgRNA.
(C) An example chromatogram showing perfect Eml4-Alk genomic junction, as w
plicons. Pred., sequence of the predicted genomic junction of Eml4-Alk rearrang
(D) Representative chromatogram of Eml4-Alk fusion transcripts obtained from m
Cell Rebut not in control mice (zero out of three p53/ mice and zero
out of three p53+/ mice) (Figure 3A). Tumors were composed
of atypical epithelial cells that showed a strong positivity for
cytokeratin and a high proliferation index as determined by Ki-
67 (Figure 3B). To investigate whether tumor expressed the
EML4-ALK fusion protein, we performed immunohistochemistry
(IHC) against ALK with an antibody that recognizes the mouse
ALK protein. By this approach, we detected positive cells only
in tumors frommice infectedwithEml4 andAlk sgRNAs,whereas
normal lungs in control mice did not show detectable staining
(Figure 3C). Next, we wanted to investigate whether such tumors
indeed carried the engineered Eml4-Alk rearrangement at the
genomic DNA. We first used laser capture microdissection
(LCM) to dissect tumors and isolate genomic DNA for PCR anal-
ysis. As controls, we dissected similarly sized areas of lungs from
control mice or from nontumoral areas adjacent to the tumors of
mice injected with CRISPR/Cas9 lentivirus expressing Eml4 and
Alk sgRNAs. PCR amplification demonstrated the presence of
the expectedEml4-Alk rearrangements only in theDNAextracted
from tumors, but not in both types of controls (Figure 3E). Finally,
sequencing of the genomic junction obtained from tumor DNA
confirmed the expected Eml4-Alk rearrangement generated by
DSBs initiated by CRISPR/Cas9 activity (Figure 3F).
DISCUSSION
We have described a simple, fast, and rather inexpensive
technique to model oncogenic chromosomal rearrangements
directly in adult mice and induce tumor formation. In principle,
the CRISPR/Cas9 approach to engineer chromosomal rear-
rangements could be applied to most, if not all, chromosomal
rearrangements as predicted by recent in vitro studies (Choi
and Meyerson, 2014; Torres et al., 2014). This technique is
embedded with great potential, but we showed that it is also
associated with the formation of unwanted genomic rearrange-
ments, such as genomic deletions and, possibly, duplications.
Another caveat associated with the CRISPR/Cas9 system is
the generation of undesired off-targeting, which appeared as
an important concern in original in vitro studies, but it is probably
less relevant in vivo (Duan et al., 2014; Hsu et al., 2013; Kuscu
et al., 2014; Wu et al., 2014). Thus, all these elements must be
carefully considered during the application of such technique
to cancer studies.
We expect that this approach could be complementary or
even replace time consuming approaches such as traditional
knockin targeting of ESCs and lengthy crossing of GEMMs
with different genetic backgrounds. Indeed, clear advantages
implied by such approach are the possibility of using different
cancer-relevant mouse genetic backgrounds for functional
studies. To this end, we demonstrated the feasibility of engineer-
ing Eml4-Alk rearrangements in p53/ or p53+/mice, but virtu-
ally any viable mouse background could be used. We testedgements are detectable only in mice injected with CRISPR/Cas9 and Eml4 and
ell as representative sequences of junctions identified from 17 out of 30 am-
ement.
RNA extracted from lung cells in vivo.
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Figure 3. Lung Tumors Generated by CRISPR/Cas9-Induced Eml4-Alk Rearrangements
(A) Representative histological sections of lung tumors in p53+/mice after intrapulmonary injections with twoCRISPR/Cas9 lentiviruses expressing the Eml4 and
Alk sgRNAs. Control p53+/ mice were injected with a lentiviral vector expressing CRISPR/Cas9, but not sgRNAs. Objective magnification, 103 (inset, 403).
Scale bars represent 100 mm.
(legend continued on next page)
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wild-type (WT) mice, but at 8 weeks of age, we could only find
small clusters of epithelial hyperplasia, possibly due to the
slower tumor development in WT mice as compared to p53/
or p53+/ mice. Thus, as compared to Eml4-Alk transgenic
mice, in our system, CRISPR/Cas9-induced tumorswere smaller
and less frequent, possibly due to the lower expression levels of
the Eml4-Alk fusion and the lower frequency of cells carrying the
Eml4-Alk rearrangement. Recently, it has been shown that ex-
pressing both sgRNAs in one single adenoviral vector is efficient
in inducing Eml4-Alk rearrangements and tumor development
(Maddalo et al., 2014).
Additional applications could be envisioned as the possibility
of combining several CRISPR/Cas9-mediated targeting for can-
cer studies. A recent work showed that in the liver of adult
mice, the simultaneous disruption of p53 and PTEN tumor sup-
pressors induced tumor formation (Xue et al., 2014). Therefore,
the possibility of combining CRISPR/Cas9-engineered chromo-
somal rearrangements with multiple targeted gene disruption of
oncosuppressors or oncogenes could greatly facilitate and
accelerate the study of the complexity of human cancers. The
recent generation of a Cre-dependent Cas9 knockin combined
with tissue-specific strains of Cre (Platt et al., 2014) could further
expand the potential use of the CRISPR/Cas9 system in vivo, as
several tissues such as nervous tissues or liver, skin, and bone
marrow could be targeted by this technology. To this end,
tissue-specific delivery methods to many organs could be easily
adapted to the delivery of sgRNAs for the generation of a variety
of tissue-specific genomic rearrangements.
EXPERIMENTAL PROCEDURES
Mice
All the animal experiments were approved by the Boston Children’s Hospital
(BCH) Institutional Animal Care and Use Committee. This review was conduct-
ed in accordance with the standards outlined in the National Research Coun-
cil’s Guide for the Care and Use of Laboratory Animals and BCH’s PHS
Assurance.
Cell Culture
Human embryonic kidney 293T (HEK293T) and ASB-XIV cell lines were grown
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum. Primary fibroblast cells were isolated frommouse tail, immortal-
ized with SV40 and maintained in DMEM/Hank’s solution.
CRISPR sgRNA Design and Cloning
Alk sgRNA and Eml4 sgRNA targeted sites were designed manually and
checked in silico. Oligomers were annealed and cloned in the BsmBI restric-
tion site of pHKO5 in order to achieve stable expression (Ran et al., 2013).
Sequences of Alk and Eml4 sgRNAs are listed in Table S1.(B) Immunohistochemical staining for cytokeratin AE1/AE3 (top) and the prolifera
injected with two CRISPR/Cas9 lentiviruses expressing the Eml4 and Alk sgRNA
(C) Immunohistochemical staining for ALK in two representative lung tumors from
Eml4 and Alk sgRNAs (top), healthy tissue from the same animals (bottom left), a
(D) Representative tumor and healthy lung areas before (left) and after (right) LCM
(E) PCR assay on genomic DNA obtained from microdissected normal lung area
mice) or nontumoral areas and tumors frommice injected with CRISPR/Cas9 lentiv
tumors) demonstrates the presence of Eml4-Alk rearrangements in lung tumors,
with three independent tumors out of four independent experiments. DNA from AS
used as a positive control for Eml4-Alk rearrangement.
(F) An example chromatogram showing an Eml4-Alk genomic junction in lung tum
Cell ReLentivirus Production and Purification
To produce the lentiviruses, HEK293T cells were seeded at70% confluence
in 10 cm dishes the day before transfection in D10 media (DMEM supple-
mented with 10% fetal bovine serum). For each dish, 18 mg of lentiCRISPR
plasmid and 3.6 mg of packaging plasmids (pVSV-G, REV, 8.74) were cotrans-
fected into HEK293T cells using a calcium phosphate transfection kit (Clon-
tech) following themanufacturer’s recommended protocol. After 30 hr, viruses
were harvested and concentrated by ultracentrifugation at 50,000 3 g for 2 hr
at 4C and resuspended with sterile 1X PBS. Aliquots were stored at 80C.
To evaluate the viral titers, we transduced ASB-XIV or mouse fibroblasts
with increasing dilutions of the lentivirus and then selected cells with puromy-
cin, as the lentiviral vectors express the puromycin resistance gene. Even if
puromycin selection likely underestimates the number of infectious particles,
by counting the numbers of puromycin-resistant cells, we calculated that
our lentiviruses contained at least a titer of 1–2 3 106/ml infectious particles,
with slight variations among different preparations. As we used 40 ml of virus
for each mouse inoculation, we estimated that we inoculated 4–83 104 infec-
tious particles/mouse.
Cell Transduction, Puromycin Selection, and Surveyor Assays
For transduction of fibroblasts or ASB-XIV cells with CRISPR/Cas9 lentivirus,
we seeded 2 3 104 fibroblasts or 8 3 104 ASB-XIV cells into six-well plates.
After 24 hr, transduction was performed in fresh media supplemented with
8 mg/ml polybrene (Sigma-Aldrich), and 48 hr later, optimal puromycin concen-
tration was added for selection (6 mg/ml for fibroblasts, 1 mg/ml for ASB-XIV)
until noninfected control group cells were completely dead. The SURVEYOR
assay was performed as described previously (Cong et al., 2013). Primers
used for PCR amplifications are indicated in Table S1.
In Vivo Lentiviral Transduction
Mice were inoculated with lentiviruses either by intratracheal inoculation
(Simpson et al., 2001) or by direct intrapulmonary injection (Onn et al.,
2003). Briefly, for intratracheal inoculation, a total volume of 40 ml from the
different lentiviral combinations was inoculated into 8-week-old BALB/c
mice as previously described (Blasco et al., 2011). For intrapulmonary injec-
tions, 40 ml volume was injected into the left lobule of 8-week-old mice as
previously described (Onn et al., 2003). Mice were sacrificed 6 days after in-
tratracheal inoculations or intrapulmonary injections for molecular studies
and 8 weeks after intrapulmonary injections for tumor studies. DNA was ob-
tained from the lungs of these mice following the classical phenol/chloroform
extraction.
PCR and RT-PCR for Eml4-Alk Rearrangements
PCR reactions for the different types of genomic rearrangements were per-
formed using DNA from transduced cell lines and lungs as indicated above.
Primers used for PCR amplifications are indicated in Table S1. In vivo rear-
rangements were identified by nested PCR. In a first round of 18 cycles,
1 mg of DNA was used for every reaction. In a second round of 25 cycles,
1 ml of the previous round was used for every reaction. Primers used for
PCR amplifications are indicated in Table S1.
For RT-PCR, cDNA synthesis was performed from extracted total RNA and
nested PCR was performed for determining the mRNA fusion transcripts orig-
inating from the Eml4-Alk rearrangement. RT-PCR reactions were sequencedtion marker Ki-67 (bottom) of a representative lung tumor from a p53+/mouse
s.
a p53+/ mouse injected with two CRISPR/Cas9 lentiviruses expressing the
nd a human ALK-rearranged NSCLC (bottom right).
isolation. Scale bars represent 150 mm.
s of mice injected with control CRISPR/Cas9 lentivirus (Lung areas of Control
iruses expressing both the Eml4 and Alk sgRNAs (Normal LCM areas and Lung
but not in control samples. Gel depicts one representative experiment of LCM
B-XIV cells infected with lentiviruses encoding both Elm4 and Alk sgRNAs was
ors from Eml4/Alk sgRNAs CRISPR/Cas9 lentivirus-injected mice.
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to confirm the Eml4-Alk in frame fusion. Primers used for PCR amplifications
are indicated in Table S1.
Immunohistochemistry and LCM
Formalin-fixed paraffin-embedded lung sections were stained with H&E and
cytokeratin AE1/AE3 in order to unambiguously detect tumor cells. ALK immu-
nostainingwasperformedusing ananti-ALK rabbitmonoclonal antibody (clone
sp8, Abcam) and Ki-67 immunostaining with a rabbit monoclonal (clone SP6,
Master Diagnostica). The consecutive sections were used for the LCM using
a PALMMicroBeam System (Carl Zeiss) controlled with PALM Robosoftware.
Approximately 300–500 microdissected cells per region (either tumor cells or
normal lung) were captured into caps of 0.5 ml PCR tubes and stored at
room temperature. DNAwas extracted andprocessed for nestedPCR. Primers
used for PCR amplifications are indicated in Table S1.
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